Nuvation Bio (NUVB) Non-Current Deferred Tax Liability (2024 - 2025)
Nuvation Bio (NUVB) posted quarterly Non-Current Deferred Tax Liability of $4.4 million for Q4 2024.
Nuvation Bio (NUVB) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
Nuvation Bio (NUVB) has reported Non-Current Deferred Tax Liability for 1 consecutive years, with $4.4 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Non-Current Deferred Tax Liability changed N/A year-over-year to $4.4 million; the TTM figure through Dec 2024 stood at $4.4 million (changed N/A YoY), while the FY2024 annual figure was $4.4 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability held at $4.4 million in Q4 2024 per NUVB's latest filing.
- Across five years, Non-Current Deferred Tax Liability topped out at $4.4 million in Q4 2024 and bottomed at $4.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 811,000.00 |
| Dec 31, 2025 | 811,000.00 |
| Dec 31, 2024 | 4.44 Mn |
| Dec 31, 2024 | 4.44 Mn |